Skip Navigation


Annals of Oncology Advance Access originally published online on June 9, 2006
Annals of Oncology 2006 17(12):1743-1747; doi:10.1093/annonc/mdl117
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/12/1743    most recent
mdl117v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mornex, F
Right arrow Articles by Girard, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mornex, F
Right arrow Articles by Girard, N
Related Collections
Right arrow 2006 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

reviews

Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art

F Mornex and N Girard

Department of Radiotherapy-Oncology, Centre Hospitalier Lyon-Sud, Lyon, France

Correspondence to: Prof. F. Mornex, Département de Radiothérapie-Oncologie, Centre hospitalier Lyon-Sud, 165, Chemin du Grand Revoyet, 69495 Pierre-Bénite cedex, France. Tel: (+33) 478864253; Fax: (+33) 478864265; E-mail: francoise.mornex{at}chu-lyon.fr

Stage III non-small cell lung cancer (NSCLC) treatment is evolving. There are several choices available regarding which chemotherapy to use and how to optimally combine them with radiotherapy. Gemcitabine (Gemzar®, Eli Lilly and Company, Indianapolis, USA) is a chemotherapeutic agent with activity in NSCLC, and preclinical studies have shown that gemcitabine is a potent radiosensitizer. These two characteristics make gemcitabine a potential option when treating patients with stage III NSCLC. This review article describes the efficacy and tolerance of gemcitabine when combined with radiation in those patients. Gemcitabine used concurrently with radiation, as an induction regimen before radiation, and as a consolidation regimen after radiation is reviewed.

Key words: gemcitabine, radiotherapy, chemotherapy, chemoradiation, non-small cell lung cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.